FamiCord AG (FRA:V3V)

Germany flag Germany · Delayed Price · Currency is EUR
4.020
+0.040 (1.01%)
Last updated: May 13, 2025
-12.61%
Market Cap 69.38M
Revenue (ttm) 82.18M
Net Income (ttm) -12.14M
Shares Out n/a
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 100
Average Volume 5,031
Open 4.020
Previous Close 3.980
Day's Range 4.020 - 4.020
52-Week Range 3.700 - 4.940
Beta n/a
RSI 46.61
Earnings Date Apr 30, 2025

About FamiCord AG

FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the compa... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1997
Employees 745
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol V3V
Full Company Profile

Financial Performance

In 2024, FamiCord AG's revenue was 82.18 million, an increase of 6.65% compared to the previous year's 77.06 million. Losses were -12.14 million, 550.7% more than in 2023.

Financial Statements

News

FamiCord AG Surpasses 2024 Earnings with Vita 34 Boost, Early Figures Show

FamiCord AG, Europe's top cell bank, surpassed its 2024 earnings forecast, with revenue hitting EUR 82.2 million and EBITDA at EUR 8.8 million, outpacing expectations by nearly 10%. Jetzt den vollstän...

4 weeks ago - Wallstreet:Online